Spotlight of the month: Unified Patent Court captures 15% of European patent litigation but still far from being primary European patent court
Changes to the proposed new medicinal products Directive have been approved by the EU Parliament – do they shift the balance between generics and innovators and are they TRIPS compliant?
Mathys & Squire files Petition for Review for Ipsen Bioinnovation
Mathys & Squire recognised as one of Europe’s leading patent firms in the Financial Times 2024 rankings
Fifteen Mathys & Squire attorneys recognised in IAM Patent 1000 2024
Spotlight of the month: MS-RT launches its new range of innovative sport-inspired Ford vehicle designs with the all-new Ford Ranger MS-RT and Transit Custom MS-RT
The supermarket battle continues: Tesco and Lidl clash in UK Court of Appeal
Beyond misconceptions: Exploring the patentability and challenges associated with AI-driven bioinformatics innovations in Europe
Where next for patentability of AI inventions in the UK?
A further blow to transparency at the UPC
Mathys Matters January 2024
In this edition:
Spotlight of the month: UPC Court of Appeal interprets law narrowly in transparency test case
EPO announces fee increases from 1 April 2024
UK banks lag behind US banks in innovation – only 290 patents filed in the last decade
How do opposition rates impact opt-outs?
Mathys & Squire patent team and four Partners recognised in JUVE Patent UK rankings for 2024.
Mathys Matters December 2023
In this edition:
Spotlight of the month: Court hearing on public access to evidence in Unified Patent Court to be held in February 2024
UK Supreme Court Decision on AI Inventorship
COP28 summary: a move away from fossil fuels and the Green Climate Fund
Mathys & Squire Partners have earned recognition in IAM Strategy 300 Global Leaders 2024
Patenting AI inventions: Major about-turn at the UKIPO